Early onset Alzheimer’s disease, which accounts for approximately 2-3% of AD cases, is a hereditary condition that is strongly associated with mutations in presenilin-1 (PSEN1), amyloid precursor protein (APP) and presenilin-2 (PSEN2) genes. Late onset Alzheimer’s disease occurs after the age of 65 and accounts for the vast majority of cases.
A combination of factors increase the risk of developing Alzheimer’s disease. One of the strongest risk factors is having two copies of the APOE4 allele, which increases the risk of developing late onset Alzheimer’s disease by approximately 15 times.
Frontotemporal dementia (FTD) refers to a spectrum of clinical diseases that may have several different underlying pathologies. Frontotemporal dementia can be sporadic or associated with mutations in the MAPT (microtubule-associated protein tau) and progranulin genes, and C9ORF72 repeat expansions.
These genetic mutations can lead to accumulation of TDP43 protein or tangles of MAPT (tau) protein. Currently, there are no approved treatments or reliable biomarkers for frontotemporal dementia. There is a need for in vitro human cell models for frontotemporal dementia and Alzheimer’s disease that can be used to accelerate research and assist in the development of new drugs to treat these disorders.
Alzheimer's Disease
Human iPSC-derived neural stem cells from Alzheimer’s disease patients
Fibroblasts from patients, clinically diagnosed with Alzheimer’s disease, were reprogrammed to iPSCs using our footprint-free episomal reprogramming method and then differentiated to neural stem cells using our chemically defined cortical neural induction method. Neural stem cells are available from Alzheimer’s patients with mutations in the presenilin-1 (PSEN1) and presenilin-2 (PSEN2) genes as well as a patient homozygous for the APOE4 allele. Neural stem cells from healthy donor iPSCs are also available as suitable controls.
Product ax0019 is the healthy isogenic control for the following cell lines:
Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (APOE4 HOM)
ax0111
Fibroblasts (87 Yr Female)
1.5 million cells
Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (PSEN1 L286V)
ax0112
Fibroblasts (38 Yr Female)
1.5 million cells
Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (PSEN1 M146L)
ax0113
Fibroblasts (53 Yr Male)
1.5 million cells
Human iPSC-Derived Neural Stem Cells – Alzheimer’s Disease Patient (PSEN1 A246E)
ax0114
Fibroblasts (31 Yr Female)
1.5 million cells
axolGEM iPSC-Derived Neural Stem Cells LRRK2 G2019S HOM
ax0310
Fibroblasts (64 Yr Donor)
1.5 million cells
axolGEM iPSC-Derived Neural Stem Cells LRRK2 G2019S HET
ax0311-kit
Fibroblasts (64 Yr Donor)
1.5 million cells
axolGEM iPSC-Derived Neural Stem Cells MAPT R406W HET
ax0321
Fibroblasts (64 Yr Donor)
Frontotemporal dementia, parkinsonism & Alzheimer's disease
axolGEM iPSC-Derived Neural Stem Cells MAPT V337M HOM
ax0322
Fibroblasts (64 Yr Donor)
1.5 million cells & Neural Plating-XF Medium
axolGEM iPSC-Derived Neural Stem Cells MAPT P301L HOM
ax0324
Fibroblasts (64 Yr Donor)
1.5 million cells & Neural Plating-XF Medium
axolGEM iPSC-Derived Neural Stem Cells MAPT P301L HET
ax0325
Fibroblasts (64 Yr Donor)
1.5 million cells & Neural Plating-XF Medium